Comments
Ranbaxy Laboratories on Tuesday said that it will start marketing Daiichi Sankyo's products in Singapore.
From March 1, Ranbaxy will market four products of Daiichi Sankyo including Cravit (levofloxacin) tab and Cravit IV in Singapore.
The products were previously commercialised by Kyowa Hakko Bio Singapore Pte Ltd in the country. Early this year, Daiichi Sankyo and Kyowa Hakko Bio agreed to transfer the marketing rights of the products from Kyowa Hakko Bio to Ranbaxy.
Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class that is used to treat a broad range of infections
“We are pleased to announce the first synergistic business development with Ranbaxy in ASEAN,” said Mr Joji Nakayama, President & CEO of Daiichi Sankyo. “We are determined to work with Ranbaxy to further serve diversifying medical needs in this strongly emerging region.”
Commenting on the development, Mr Arun Sawhney, Managing Director of Ranbaxy, said, “Ranbaxy has a strong foot hold in the ASEAN region. We will use our marketing strengths to offer innovative medicines from Daiichi Sankyo in this fast growing region, beginning with Singapore. This move will definitely widen our product offering while deepening our commitment to doctors and patients. I believe we will see many more synergies in time, emerging from our Hybrid Business Model with Daiichi Sankyo.” Ranbaxy is already selling Daiichi Sankyo's products in Mexico, Romania and South Africa.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.